Shots:

• Hisamitsu to receive upfront- milestone based on the regulatory approval and royalties on sales of product. Kyowa Kirin to get exclusive commercialization rights for Hisamitsu’s HP-3000- post marketing approval in Japan
• The focus of the agreement is to develop & commercialize therapies for Parkinson’s disease developed using Hisamitsu’s TDDS (Transdermal Drug Delivery System) technology
• Hisamitsu’s HP-3000 is a transdermal skin patch- evaluated in P-III study for Parkinson's disease has met 1EPs- with its NDA filled in Sept-2018 and expected approval in Feb- 2020

 Ref: Kyowa Kirin | Image:  Thailand Medical News